The standard treatment for chronic and painful skin damage in people with mild to moderate hidradenitis suppurativa is initially topical application of anti-inflammatory and antibiotic ointments. On behalf of the Federal Joint Committee (G-BA) in Germany, the Institute for Quality and Efficiency in Health Care (IQWiG) investigated the advantages and disadvantages of irradiating inflamed skin with a combination of intense pulsed light and radiofrequency, in addition to topical antibiotic therapy.
IQWiG's conclusion is based on the results of a high-quality randomized trial: Patients with Stage I and II hidradenitis suppurativa (according to the Hurley score) benefit from combination therapy consisting of topical antibiotic therapy plus skin irradiation, as this is substantially more effective at improving deep and extensive skin damage caused by inflammation or purulent abscesses than topical antibiotic therapy alone.
The primary treatment goal can thus be better achieved with combination therapy than with antibiotic monotherapy. The study results for other endpoints such as anxiety, depression, pain and health-related quality of life showed no relevant differences between the two treatment groups. Although there were statistically small differences in favour of additional skin irradiation in terms of pain and quality of life, these were too small to be considered regularly perceptible and therefore relevant. Temporary side effects such as redness, swelling or itching of the treated skin occasionally occurred after skin irradiation, but these were not serious.
Chronic condition with a high disease burden
Hidradenitis suppurativa (also known as acne inversa) is a chronic skin condition that causes inflammation of the hair follicles or sebaceous glands, resulting in painful, pus-filled nodules that can develop into larger abscesses. This skin disease can spread to large areas of the body, particularly the armpits and groin, as well as the genital and anal regions. Because the inflammation of the skin often makes any movement in the hip and shoulder joints painful, affected patients can experience severe restrictions in their everyday lives.
Relieving skin damage and pain through treatment and the resulting improvement in quality of life are a priority for patients. This was confirmed in discussions with patients conducted by IQWiG in order to obtain information from the patient perspective for the benefit assessment. Therefore, treating symptoms for a few weeks appears to be insufficient for a lifelong and debilitating condition. However, it remains unclear whether continuous maintenance therapy with radiation (also without the concomitant administration of antibiotics) offers any advantages, as the relevant study only permits a comparison over a period of 16 weeks. After this time, all patients were able to receive the same treatments. Furthermore, the necessity of skin surgery, which can be very stressful for patients, could not be assessed based on the available study data.
Process of report production
In April 2024, the G-BA commissioned IQWiG to assess skin irradiation with intense pulsed light and radiofrequency therapy in the treatment of Stage I and II hidradenitis suppurativa (Hurley score). In December 2024, IQWiG published its preliminary findings in a preliminary report and invited comments for discussion. After completion of the commenting procedure, the project team revised the preliminary report and submitted it to the contracting agency, the G-BA, as a final report in January 2025, which was published in February 2025. The written comments received were published in a separate document at the same time as the final report. An English translation of the report was published in November 2025.